Holistic Financial Partners Acquires 601 Shares of Johnson & Johnson (NYSE:JNJ)

Holistic Financial Partners grew its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 30.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,599 shares of the company’s stock after purchasing an additional 601 shares during the quarter. Holistic Financial Partners’ holdings in Johnson & Johnson were worth $407,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Keener Financial Planning LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $40,000. WFA Asset Management Corp grew its position in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the last quarter. Disciplined Equity Management Inc. acquired a new stake in Johnson & Johnson in the 4th quarter worth $45,000. Altshuler Shaham Ltd grew its position in Johnson & Johnson by 37.8% in the 3rd quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock worth $49,000 after purchasing an additional 87 shares during the last quarter. Finally, Pacific Capital Wealth Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter worth $61,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research report on Wednesday, May 22nd. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “neutral” rating and a $160.00 target price on the stock. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $174.80.

Check Out Our Latest Analysis on JNJ

Johnson & Johnson Price Performance

Shares of JNJ stock traded up $0.73 during trading hours on Thursday, reaching $145.17. 3,067,408 shares of the company were exchanged, compared to its average volume of 7,376,717. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The stock’s fifty day moving average is $150.65 and its two-hundred day moving average is $155.00. The company has a market cap of $349.38 billion, a price-to-earnings ratio of 9.03, a P/E/G ratio of 2.40 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period in the prior year, the business earned $2.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.